{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:32Z","timestamp":1761870512003,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.clml.2012.09.016","type":"journal-article","created":{"date-parts":[[2012,11,13]],"date-time":"2012-11-13T05:34:34Z","timestamp":1352784874000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes"],"prefix":"10.1016","volume":"13","author":[{"given":"Roberto","family":"Castelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramona","family":"Cassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.09.016_bib1","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"7","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib2","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Myelodysplastic syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.016_bib3","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib4","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.016_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2174\/156800911796798940","article-title":"Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia","volume":"11","author":"Szmigielska-Kap3on","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2012.09.016_bib6","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2141.2007.06537.x","article-title":"World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes","volume":"137","author":"Bernasconi","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.016_bib8","first-page":"1168","article-title":"Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes","volume":"90","author":"Sol\u00e9","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.09.016_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of long arm of no. 5 chromosome","volume":"251","author":"Van den Berghe","year":"1974","journal-title":"Nature"},{"key":"10.1016\/j.clml.2012.09.016_bib10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3324\/haematol.13377","article-title":"Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome)","volume":"93","author":"Cazzola","year":"2008","journal-title":"Haematologica"},{"issue":"suppl","key":"10.1016\/j.clml.2012.09.016_bib11","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1053\/j.seminoncol.2005.06.020","article-title":"Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)","volume":"32","author":"List","year":"2005","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clml.2012.09.016_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2174\/156800911798073104","article-title":"Antiangiogenesis in myelodysplastic syndrome","volume":"11","author":"Aguayo","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clml.2012.09.016_bib13","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2010.06.003","article-title":"Effects of the bone marrow microenvironment on hematopoietic malignancy","volume":"48","author":"Askmyr","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clml.2012.09.016_bib14","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/asheducation-2011.1.556","article-title":"Immunomodulating drugs in myelodysplastic syndromes","volume":"2011","author":"Ad\u00e8s","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2012.09.016_bib15","first-page":"719","article-title":"WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients","volume":"45","author":"Iyer","year":"1971","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.clml.2012.09.016_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.016_bib17","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/08923973.2012.658921","article-title":"Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice","volume":"34","author":"Castelli","year":"2012","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.clml.2012.09.016_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/187152011795347487","article-title":"Lenalidomide: current understanding of mechanistic properties","volume":"11","author":"Tageja","year":"2011","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.clml.2012.09.016_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ajh.21610","article-title":"Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofibrosis","volume":"85","author":"Lacy","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.016_bib20","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","article-title":"Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life","volume":"106","author":"Balducci","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.09.016_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0959-8049(02)00628-7","article-title":"Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa","volume":"39","author":"Patrick","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2012.09.016_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.0902-4441.2003.00183.x","article-title":"Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report","volume":"72","author":"Clavio","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2012.09.016_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1995.tb08909.x","article-title":"Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies","volume":"89","author":"Hellstr\u00f6m-Lindberg","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.016_bib24","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076","article-title":"Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy","volume":"87","author":"Negrin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib25","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood-2007-06-096370","article-title":"Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib26","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03204.x","article-title":"The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes","volume":"115","author":"Zorat","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.016_bib27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2004.11.008","article-title":"Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes","volume":"29","author":"Invernizzi","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.09.016_bib28","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.leukres.2008.06.005","article-title":"Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes","volume":"33","author":"Tamburini","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.09.016_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.leukres.2007.11.037","article-title":"Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide","volume":"32","author":"Kelaidi","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.09.016_bib30","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.09.016_bib31","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/leu.2009.296","article-title":"Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis","volume":"24","author":"Matsuoka","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.016_bib32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00277-005-1054-0","article-title":"Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup","volume":"84","author":"Giagounidis","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.09.016_bib33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.2011.08979.x","article-title":"Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents","volume":"156","author":"Sibon","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.09.016_bib34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.016_bib35","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"List","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.09.016_bib36","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib37","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.leukres.2011.05.034","article-title":"Treatment by lenalidomide in lower risk myelodysplastic syndrome with 5q deletion: the GFM experience","volume":"35","author":"Le Bras","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2012.09.016_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"108","author":"Chang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib39","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/leu.2009.279","article-title":"Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients","volume":"24","author":"Chan","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.016_bib40","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3324\/haematol.2009.010876","article-title":"Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion","volume":"95","author":"Ximeri","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.09.016_bib41","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1182\/blood-2008-08-175778","article-title":"Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study","volume":"113","author":"Ad\u00e8s","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib42","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3324\/haematol.2010.039669","article-title":"Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities","volume":"96","author":"M\u00f6llg\u00e5rd","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2012.09.016_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.22246","article-title":"Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management","volume":"87","author":"Estey","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.016_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.blre.2011.11.001","article-title":"Refining existing therapy improved biologic insights","volume":"26","author":"Schecter","year":"2012","journal-title":"Bloods Rev"},{"key":"10.1016\/j.clml.2012.09.016_bib45","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2009.26.0745","article-title":"Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes","volume":"28","author":"Sekeres","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.016_bib46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/leu.2011.284","article-title":"Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype","volume":"26","author":"Scherman","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.016_bib47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/leu.2011.3","article-title":"Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement","volume":"25","author":"Dimopoulos","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2012.09.016_bib48","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1182\/blood-2002-06-1674","article-title":"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy","volume":"100","author":"Cavo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.09.016_bib49","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1538-7836.2003.00084.x","article-title":"Thalidomide and thrombosis in multiple myeloma","volume":"1","author":"Barbui","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clml.2012.09.016_bib50","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/10428190400015675","article-title":"Arterial thrombosis in four patients treated with thalidomide","volume":"46","author":"Scarpace","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.09.016_bib51","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/157016110791330799","article-title":"Thromboembolic complications in malignant haematological disorders","volume":"8","author":"Castelli","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.clml.2012.09.016_bib52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00277-004-0891-6","article-title":"Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone","volume":"83","author":"Corso","year":"2004","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2012.09.016_bib53","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ajh.22114","article-title":"Inflammation, TNF\u03b1 and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia","volume":"86","author":"Aue","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.09.016_bib54","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2009.07.004","article-title":"Patients with antiphospholipid syndrome display endothelial perturbation","volume":"34","author":"Cugno","year":"2010","journal-title":"J Autoimmun"},{"key":"10.1016\/j.clml.2012.09.016_bib55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.thromres.2010.11.018","article-title":"Immunomodulatory drugs increase endothelial tissue factor expression in vitro","volume":"127","author":"Valsami","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2012.09.016_bib56","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/MBC.0b013e328348629d","article-title":"Activation of coagulation by a thalidomide-based regimen","volume":"22","author":"Hoshi","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.clml.2012.09.016_bib57","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.21.6945","article-title":"Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms","volume":"27","author":"Hadland","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.09.016_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4419-7073-2_14","article-title":"Clinical practice guidelines for the use of erythroid-stimulating agents: Asco, EORTC, NCCN","volume":"157","author":"Lichtin","year":"2011","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.clml.2012.09.016_bib59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3324\/haematol.2011.045914","article-title":"Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion","volume":"97","author":"Ad\u00e8s","year":"2012","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:38Z","timestamp":1761870218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2152265012002005"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}